SuperGen, Inc. announced that a contract has been executed to terminate the distribution of Nipent (pentostatin for injection) by Wyeth and transition distribution to SuperGen, Inc. The company paid Wyeth a $2.1 million dollar early termination fee, making it effective June 1, 2006.

SuperGen and Wyeth will collaborate to ensure uninterrupted distribution services during the transition period. Distribution and marketing for Nipent in Europe will be managed by SuperGen's subsidiary, EuroGen Pharmaceuticals Limited, which is based in Cheltenham, United Kingdom.

EuroGen will have a commercial presence at the upcoming European Haematology Association (EHA) meeting in Amsterdam, The Netherlands. Additionally Nipent will be discussed within a symposium on June 15 at EHA entitled "M.D. Anderson Cancer Center Approach to Patients with Haematological Malignancies," chaired by Michael J. Keating, M.D.

Nipent (pentostatin for injection) is currently approved as a single- agent treatment for patients with Hairy Cell Leukaemia in the United States and selective counties within Europe, and is not approved as either a single agent or as part of a combination regimen for treatment for any other indication in any territory.